CLINICAL TRIALS PROFILE FOR FINACEA

All Clinical Trials for FINACEA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01038869 ↗	Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)	Completed	Bayer	Phase 4	2009-12-01	Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01038869 ↗	Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)	Completed	Derm Research, PLLC	Phase 4	2009-12-01	Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01139008 ↗	Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin	Completed	Galderma Laboratories, L.P.	Phase 4	2010-06-01	The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
NCT01139047 ↗	Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin	Completed	Galderma Laboratories, L.P.	Phase 4	2010-06-01	The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
NCT01631656 ↗	Combination Gel and Vascular ND in Mild to Moderate Rosacea	Completed	Bayer	N/A	2010-07-01	This is a single center, open-label, split-face, prospective study of ten to fifteen subjects seeking vascular laser therapy for the treatment of mild to moderate rosacea. Subjects will be screened for eligibility for vascular laser therapy outside of the confines of this protocol. Once approved for laser, subjects will be screened for study enrollment and topical treatment of their rosacea at the Screening/Baseline visit. All subjects will receive Finacea 15% gel and will be instructed to apply the study drug to one half of the face, twice daily. Drug application will be modified just prior to and after the subjects' laser treatment to reduce irritation. Subjects will undergo Vascular Nd:Yag laser therapy to involved areas over the whole face two weeks after initiating Finacea treatment. Subjects will continue to use Finacea gel to one half of the face for the duration of the study.

Clinical Trial Conditions for FINACEA

Condition Name

Condition Name for FINACEA
Intervention	Trials
Rosacea	6
Skin Manifestations	2
Central Centrifugal Cicatricial Alopecia	1
Post Inflammatory Hyperpigmentation	1

Condition MeSH

Condition MeSH for FINACEA
Intervention	Trials
Rosacea	8
Skin Manifestations	2
Alopecia Areata	1
Alopecia	1

Clinical Trial Locations for FINACEA

Trials by Country

Trials by Country for FINACEA
Location	Trials
United States	39

Trials by US State

Trials by US State for FINACEA
Location	Trials
North Carolina	5
Texas	3
Kentucky	3
Louisiana	2
Indiana	2

Clinical Trial Progress for FINACEA

Clinical Trial Phase

Clinical Trial Phase for FINACEA
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	3
Phase 1	1

Clinical Trial Status

Clinical Trial Status for FINACEA
Clinical Trial Phase	Trials
Completed	11
Not yet recruiting	1

Clinical Trial Sponsors for FINACEA

Sponsor Name

Sponsor Name for FINACEA
Sponsor	Trials
Bayer	3
Galderma Laboratories, L.P.	2
Wake Forest University Health Sciences	2

Sponsor Type

Sponsor Type for FINACEA
Sponsor	Trials
Industry	12
Other	6